0
0
BOSTON, MA – A new study from Mass General Brigham suggests that a nasal spray targeting neuroinflammation could be an effective treatment for traumatic brain injury (TBI). The research, conducted on a mouse model of TBI, found that the nasal spray, containing anti-CD3, reduced damage to the central nervous system and behavioral deficits.
The research team examined the monoclonal antibody Foralumab, made by Tiziana, which has been tested in clinical trials for patients with multiple sclerosis, Alzheimer’s disease, and other conditions. The1 study identified how the spray modulates immune response, correlating with improved neurological outcomes, including less anxiety, cognitive decline, and improved motor skills.
Researchers were able to learn about immune response over time and compare the immune responses and effects of TBI in the mice. The next step involves2 translating these preclinical findings to human patients, with the hope that this treatment could be used on a variety of traumatic brain injury patients.
Disclaimer: This news article is based on a preclinical study in mice and should not be interpreted as definitive medical advice. Further research, including human clinical trials, is needed to confirm the safety and efficacy of this nasal spray for treating traumatic brain injury in humans. The information provided here is for informational purposes only and does not substitute professional medical guidance. If you have concerns about TBI, please seek advice from a qualified healthcare provider.
Mass General Brigham. “Nasal spray shows preclinical promise for treating traumatic brain injury.” ScienceDaily. ScienceDaily, 27 February 2025. <www.sciencedaily.com
